prostate cancer has to be of intermediate-risk based on at least one of the three following criteria: PSA between 10 ng/ml and 20 ng/ml, and/or a Gleason score of 7 and/or a T2B. Karnofsky performance status ≥ 60% and consequently performance status ECOG 0-2.
the patient has to be the beneficiary of the social security system (order n° 2006-477 from April 26th 2006);
the signed consent form.
You may not be if
PSA level \> 20;
Gleason \> 7;
clinical T3A or T3B or MRI (a simple suspicion/ doubt on the MRI regarding the T3A won't be an exclusion criterion);
prostate volume \> 60 cc;
pelvic lymph nodes involvement at dissection or imaging (ADP \> 1.5 cm);
concurrent hormone therapy;
the presence of distant metastasis (M1);
history of abdominal or pelvic irradiation;
history of prostate resection in the previous 6 months and/or not allowing the implantation of markers;
history of uncontrolled cancer and/or treated since less than 5 years (excepting the basal-cell carcinoma);
urinary discomfort with an IPSS (International Prostate Symptom Score) \> 15 (without alpha-blocking);
inflammatory bowel disorder such as ulcerative colitis or the Crohn's disease;
other undergoing study that may interfere with the present study;
